INmune Bio (NASDAQ:INMB) Stock Price Up 2.5%

INmune Bio, Inc. (NASDAQ:INMBGet Rating)’s share price rose 2.5% during mid-day trading on Friday . The company traded as high as $7.78 and last traded at $7.36. Approximately 33,300 shares were traded during trading, a decline of 38% from the average daily volume of 53,659 shares. The stock had previously closed at $7.18.

INmune Bio Price Performance

The business’s 50 day simple moving average is $7.35 and its 200-day simple moving average is $7.69. The stock has a market capitalization of $132.08 million, a price-to-earnings ratio of -4.94 and a beta of 1.94. The company has a debt-to-equity ratio of 0.13, a quick ratio of 5.53 and a current ratio of 5.53.

INmune Bio (NASDAQ:INMBGet Rating) last issued its quarterly earnings results on Thursday, March 2nd. The company reported ($0.32) earnings per share for the quarter. The company had revenue of $0.10 million during the quarter. INmune Bio had a negative return on equity of 43.26% and a negative net margin of 10,816.06%.

Institutional Trading of INmune Bio

A number of institutional investors have recently made changes to their positions in INMB. Susquehanna International Group LLP lifted its stake in shares of INmune Bio by 189.6% in the 1st quarter. Susquehanna International Group LLP now owns 70,637 shares of the company’s stock worth $456,000 after acquiring an additional 46,243 shares during the period. Vanguard Group Inc. lifted its stake in INmune Bio by 8.3% during the first quarter. Vanguard Group Inc. now owns 553,638 shares of the company’s stock valued at $4,661,000 after purchasing an additional 42,609 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in INmune Bio during the first quarter valued at approximately $225,000. Janney Montgomery Scott LLC lifted its stake in INmune Bio by 14.9% during the fourth quarter. Janney Montgomery Scott LLC now owns 224,579 shares of the company’s stock valued at $1,424,000 after purchasing an additional 29,093 shares during the last quarter. Finally, MAI Capital Management acquired a new stake in INmune Bio during the first quarter valued at approximately $127,000. 10.66% of the stock is owned by institutional investors and hedge funds.

About INmune Bio

(Get Rating)

INmune Bio, Inc Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Featured Articles

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.